Post-earnings recap
Reported
Mon, Aug 3, 2026
EPS actual
$-1.14
EPS est.
$-1.23
EPS surprise
+7.47%
1-day move
+0.29%
Crinetics Pharmaceuticals reported a larger-than-expected loss per share, but the stock still saw a slight increase of 0.29%. The lack of revenue and guidance may raise concerns among investors, but the positive surprise in EPS could indicate better-than-anticipated cost management. Overall, the market's reaction suggests a cautious optimism despite the revenue miss.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.14 | $-1.06 | +7.47% |
| Revenue | — | $16M | — |
No transcript is on record, and the analysis is based solely on numerical results.
Crinetics Pharmaceuticals, Inc. focuses on developing innovative therapies for rare endocrine diseases and metabolic disorders. As a player in the healthcare sector, its advancements in pharmaceuticals could significantly impact patient care and market dynamics.
Last quarter
In Q1-2026, Crinetics reported an EPS of -1.23, slightly missing estimates. The stock reacted positively, gaining 4.27% the following day.
EPS beat streak
1Q
EPS beat rate
38%
Avg EPS surprise
-1.40%
Avg 1-day reaction
+1.19%
Analysts expect Crinetics to report a loss of $1.06 per share on $16 million in revenue for Q2-2026. The market is closely watching for any signs of improvement in financial performance.
Bull case
If Crinetics can beat EPS estimates and show revenue growth, it could signal a turnaround in its financial health, attracting more investor interest.
Bear case
Conversely, if the company misses expectations again, it may raise concerns about its ability to execute on its growth strategy, leading to a potential decline in stock price.
Key metrics to watch
EPS
-1.06Earnings per share is crucial as it reflects the company's profitability and is a key indicator for investors.
Revenue
16MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Crinetics achieve an EPS closer to the consensus estimate of -1.06?
A closer alignment with expectations could boost investor confidence, while a larger loss may raise red flags about the company's financial trajectory.
Q2
What are the revenue figures for this quarter, and how do they compare to previous quarters?
Revenue performance is critical for assessing the company's growth potential and market demand for its products.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may be overly pessimistic regarding Crinetics' ability to stabilize its EPS, given the potential for unexpected revenue growth from new product developments.
Supporting evidence
The options market is pricing a significant move, indicating that investors expect volatility that could lead to a surprise.
Crinetics has a history of surprising the market, as seen in previous quarters where they exceeded expectations despite a challenging environment.
Key risk
If revenue exceeds $16 million, it could challenge the current bearish sentiment and shift investor perception.
Pre-commit to what would confirm each case.
The market is debating whether Crinetics can stabilize its financial performance after a series of misses.
Bull confirmed if
An EPS of -1.06 or better, with revenue exceeding $16 million, would confirm a positive outlook.
Bear confirmed if
An EPS worse than -1.08, with revenue falling below $16 million, would indicate ongoing challenges.
What the market is pricing for the move.
Implied Move
±17.74%
Historical Avg
±2.3%
The options market is pricing in a significant move, suggesting investors are anticipating volatility around the earnings report.
Options are pricing ±17.7% while CRNX has averaged ±2.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
59.7%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich setup in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
119.21%
of float
Insider
1.13%
of float
Holders
386
institutions
Top Holders· as of Jun 2026
FMR, LLC
15,840,219 sh · $1.3B
14.93%
0.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Crinetics beats expectations, history suggests a potential stock increase of around 1.42%, confirming a positive turnaround narrative.
In line / cautious
If results are in line but management provides cautious commentary, the stock may experience muted movement as investors reassess future growth.
Miss
A miss could lead to a decline, with historical averages suggesting a drop of around 1.90% following disappointing results.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
House only
Est. Notional
$15,001.00–$50,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Blackrock Inc.
9,758,938 sh · $829.0M
9.20%
15.1%
Farallon Capital Management LLC
8,989,098 sh · $763.6M
8.47%
7.8%
Wellington Management Group, LLP
7,131,084 sh · $605.8M
6.72%
-12.6%
Driehaus Capital Management, LLC
6,463,551 sh · $549.1M
6.09%
1.1%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Jul 30, 2026 · disclosed Sep 4, 2026
$15,001.00–$50,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.